Yutaka Atomi

Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA.

Resona Bank, Ltd. provides commercial banking services. It operates through the following segments: Personal, Corporate, and Market. The Personal segment handles financial services for individual customers including personal loans, asset management, and inherited asset consulting. The Corporate segment focuses on lending, asset management that uses trusts, real estate operations, enterprise pensions, and business growth support. The Market segment engages in funds, foreign and local exchanges, bonds, and derivatives. It also offers current and savings accounts, mortgages, debit and credit cards, pension and insurance products, online and phone banking, and investment trusts. The company was founded on May 15, 1918 and is headquartered in Osaka, Japan.

GlaxoSmithKline KK researches, develops, imports, manufactures and sells toiletry products. The company was founded on August 18, 1928 and is headquartered in Tokyo, Japan

Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The private company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million.

Tolero Pharmaceuticals, Inc. manufactures and markets pharmaceutical products. It is a clinical-stage biopharmaceutical company with a single-minded purpose to alleviate human suffering through the development of medicines to treat cancer and other serious human diseases. The company is headquartered in Lehi, UT.

ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA.

Sumitomo Mitsui Banking Corp. engages in the provision of financial services centered on banking. It operates through the following business segments: Wholesale, Retail, International, Market Sales, and Headquarters Management. The Wholesale segment covers business for customers of large and medium-sized companies in Japan. The Retail segment handles business for domestic individuals and SME customers. The International segment comprises of business for overseas Japanese and non-Japanese companies. The Market Sales segment corresponds to financial market business. The Headquarters Management segment includes all other businesses not covered by other segments. The company was founded in April 2001 and is headquartered in Tokyo, Japan.

Kyoto Pharmaceutical Industries Ltd. engages in pharmaceutical products manufacturing. Its products include pharmaceuticals to regulate high-blood pressure, Ischemic heart disease treatment, digitalis formulation, and constipation remedies. The firm also develops and produces laxatives, anti-flatulence and anti-diarrheal medicines, and decongestants and cold medicines. The company was founded on September 5, 1946 and is headquartered in Kyoto, Japan.

Part of Barclays PLC, Barclays Securities Japan Ltd. is a brokerage company based in Tokyo, Japan. Barclays Securities Japan provides brokerage services. The Japanese company was founded in 1987. Kentaro Kiso has been the CEO of the private company since 2014.

Future Brain KK is a Japanese company that engages in securities dealing and real estate management business. The private company is based in Tokyo, Japan.

Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC.

Nihon Medi-Physics Co., Ltd. is a leading manufacturer of radiopharmaceuticals, based in Japan. The Japanese company is engaged in ensuring stable supply and research and development of new products. It is also working on research and development of "theranostics," a novel medical technology to provide optimal medical service to each patient, as well as on the dissemination of nuclear medicine in Asian countries by licensing its products. Nihon Medi-Physics Co. was founded in 1973, and the CEO is Nobuhiko Tamura.

Part of Medipal Holdings Corp., Mediceo Corp. is a Japanese company that wholesales drugs and medical devices. The private company is based in Tokyo, Japan and was founded in 2004.

Part of Sumitomo Chemical Co., Ltd., Sumitomo Pharma Animal Health Co., Ltd. is a Japanese company that manufactures and supplies pharmaceuticals, food ingredients, food additives, veterinary medicines, and diagnostics. The private company is based in Osaka, Japan and was founded in 2010.

Part of Medipal Holdings Corp., MEDIE Co., Ltd. is a Japanese company that provides medical information through the internet and develops and distributes computer software and medical equipment and tools. The private company is based in Tokyo, Japan. MEDIE Co. was acquired by Medipal Holdings Corp. on June 01, 2013 for $8.05 million.

Japan Vaccine Co., Ltd. develops and markets preventive vaccines. The joint venture company is based in Tokyo, Japan.

Primetals Technologies Ltd. operates as a engineering and plant construction company. It manures of steel and iron products. The company was founded in January 2015 and is headquartered in London, the United Kingdom.

Sunovion Pharmaceuticals Europe Ltd. is a British European pharmaceutical company founded in 2013 that is dedicated to improving the lives of patients through the supply of essential medicines. The company is based in London, UK. The company commercializes and distributes a portfolio of specialty brands and hospital products in 40 countries worldwide, both directly and through strategic partnerships. The company's vision is to become a recognized partner of choice through their commercial excellence, patient focus, and presence across the globe. Sunovion Pharmaceuticals Europe aims to have a positive impact on society through their pioneering focus on their environment, social, and governance (ESG) goals.

Meltin MMI KK develops bio-signal interface technologies. It offers biosignal processing and cable-driven ststems. The company was founded by Sumio Ito, Masahoro Kasuya and Tatsuya Seki and is headquartered in Tokyo, Japan.

Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries.

Altavant Sciences, Inc. is a clinical stage biopharmaceutical company, which provides therapies that treat respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension (PAH). The company is headquartered in Cary, NC.

Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY.